Recardio
PrivateLast Round
Series A
Nov 11, 2015
Total Funding Raised
$3M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Recardio is a biotechnology company that develops small molecule therapeutics for cardiovascular diseases that promote natural regenerative capacity.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Recardio Comparables
Compare Recardio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Serca Pharmaceuticals | 77% | |
| CellProthera | 77% | |
| Prolifagen | 77% | |
Recardio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Nov 11, 2015 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased by 200%, from 0 to 2.
- Jan 20, 2026
Monthly visitors increased 2024% MoM, from 41 to 871.
Recardio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Recardio's valuation, stock price, and market status.